The drug also reduced homeostasis model assessment of insulin resistance ( HOMA-IR ) index , systolic blood pressure , and diastolic blood pressure among participants with T2DM .
The changes in hemoglobin A1c ( HbA1c ) , low-density lipoprotein cholesterol , and high-density lipoprotein cholesterol were negligible .
Subgroup analysis comparing the resveratrol supplementation doses of < 100 mg/d versus ≥ 100 mg/d revealed a significant difference in fasting plasma glucose .
In particular , the latter dose presented more favorable results .
This meta- analysis provides evidence that supplementation of resveratrol may benefit management of T2DM
Although the regular consumption of resveratrol has been known to improve glucose homeostasis and reverse insulin resistance in type 2 diabetes mellitus ( T2DM ) , the reported results are inconsistent .
Thus , we aim ed to assess the effects of resveratrol on glycemic control and insulin sensitivity among patients with T2DM .
Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.
BACKGROUND Resveratrol has been reported to lower glycemia in rodent models of type 2 diabetes associated with the stimulation of glucagon-like peptide 1 ( GLP-1 ) , which is known to slow gastric emptying , stimulate insulin secretion , and suppress glucagon secretion and energy intake . OBJECTIVE We evaluated the effects of 5 wk of resveratrol treatment on GLP-1 secretion , gastric emptying , and glycemic control in type 2 diabetes . DESIGN Fourteen patients with diet-controlled type-2 diabetes [ mean ± SEM glycated hemoglobin ( HbA1c ) : 6.4 ± 0.2 % ( 46.4 ± 2.2 mmol/mol ) ] received resveratrol ( 500 mg twice daily ) or a placebo over two 5-wk intervention periods with a 5-wk washout period in between in a double-blind , r and omized , crossover design . Before and after each intervention period ( 4 visits ) , body weight and HbA1c were measured , and patients were evaluated after an overnight fast with a st and ardized mashed-potato meal labeled with 100 μg (13)C-octanoic acid to measure blood glucose and plasma GLP-1 concentrations and gastric emptying ( breath test ) over 240 min . Daily energy intake was estimated from 3-d food diaries during the week before each visit . RESULTS Fasting and postpr and ial blood glucose and plasma total GLP-1 as well as gastric emptying were similar at each assessment , and the change in each variable from weeks 0 to 5 did not differ between resveratrol and placebo groups . Similarly , changes in HbA1c , daily energy intake , and body weight after 5 wk did not differ between the 2 treatments . CONCLUSIONS In patients with diet-controlled type 2 diabetes , 5 wk of twice-daily 500 mg-resveratrol supplementation had no effect on GLP-1 secretion , glycemic control , gastric emptying , body weight , or energy intake . Our observations do not support the use of resveratrol for improving glycemic control . This trial was registered at www.anzctr.org.au as ACTRN12613000717752
The drug also reduced homeostasis model assessment of insulin resistance ( HOMA-IR ) index , systolic blood pressure , and diastolic blood pressure among participants with T2DM .
The changes in hemoglobin A1c ( HbA1c ) , low-density lipoprotein cholesterol , and high-density lipoprotein cholesterol were negligible .
Subgroup analysis comparing the resveratrol supplementation doses of < 100 mg/d versus ≥ 100 mg/d revealed a significant difference in fasting plasma glucose .
In particular , the latter dose presented more favorable results .
This meta- analysis provides evidence that supplementation of resveratrol may benefit management of T2DM
Although the regular consumption of resveratrol has been known to improve glucose homeostasis and reverse insulin resistance in type 2 diabetes mellitus ( T2DM ) , the reported results are inconsistent .
Thus , we aim ed to assess the effects of resveratrol on glycemic control and insulin sensitivity among patients with T2DM .